579 predictions since April 2026 — each with a permalink, confidence, and public resolution status. Nothing is deleted.
| Date | Prediction | Conf. | Status |
|---|
| 2026-08-21 | Ibogaine research stays tightly restricted for veterans this year | 70% | ⏳ Pending |
| 2026-08-21 | Political pressure won't speed up the US government's MDMA therapy decision | 68% | ⏳ Pending |
| 2026-08-21 | No big psychedelic company buyouts or deals expected in the next two months | 66% | ⏳ Pending |
| 2026-08-21 | Rogan-linked FDA official draws ethics scrutiny but doesn't speed up MDMA review | 65% | ⏳ Pending |
| 2026-08-21 | Ibogaine buzz won't trigger a major psychedelic industry deal by October | 63% | ⏳ Pending |
| 2026-08-20 | FDA will demand heart-monitoring rules before ibogaine trials can expand | 70% | ⏳ Pending |
| 2026-08-20 | Heart-safety rules and DEA red tape will slow ibogaine trials despite White House hype | 68% | ⏳ Pending |
| 2026-08-20 | Journalists will expose the gap between ibogaine hype and trial reality by early October 2026 | 68% | ⏳ Pending |
| 2026-08-20 | Small ibogaine stocks that surged on White House news will likely fall back by end of September 2026 | 66% | ⏳ Pending |
| 2026-08-20 | Small ibogaine stocks fade by September; ATAI beats Compass Pathways on near-term news | 63% | ⏳ Pending |
| 2026-08-18 | Drug enforcement agency's weed stance will shape psychedelic policy too | 62% | ⏳ Pending |
| 2026-08-18 | Cybin's mushroom-derived drug works in trial but faces credibility questions | 60% | ⏳ Pending |
| 2026-08-18 | A major investigation will warn about ibogaine's heart risks within 8 weeks | 60% | ⏳ Pending |
| 2026-08-18 | Cybin's depression drug trial results expected in about 10 weeks | 58% | ⏳ Pending |
| 2026-08-18 | Positive trial results could make Cybin's stock jump 15% in one day | 58% | ⏳ Pending |
| 2026-08-17 | No psychedelic drug review panel meeting set before December 2026 | 70% | ⏳ Pending |
| 2026-08-17 | Congress won't vote on psychedelic laws this session; California leads instead | 68% | ⏳ Pending |
| 2026-08-17 | Cybin's depression drug trial succeeds, but company still needs a second study | 66% | ⏳ Pending |
| 2026-08-17 | Congress skips psychedelic legislation again; California remains the only mover | 65% | ⏳ Pending |
| 2026-08-17 | Cybin's trial results will sharply move the whole psychedelic stock sector | 62% | ⏳ Pending |
| 2026-08-15 | Presidential ibogaine buzz produces zero real government action | 80% | ⏳ Pending |
| 2026-08-15 | VA psilocybin trials show sign-up info only — no results yet | 80% | ⏳ Pending |
| 2026-08-15 | New psilocybin research papers will say 'we need more research' not 'use this now' | 75% | ⏳ Pending |
| 2026-08-15 | VA psilocybin news won't give COMPASS a new FDA boost | 72% | ⏳ Pending |
| 2026-08-15 | VA psilocybin trial spots number under 200 — media highlights the gap | 70% | ⏳ Pending |
| 2026-08-14 | VA's mushroom therapy trials will track safety, not results, by year-end | 74% | ⏳ Pending |
| 2026-08-14 | VA mushroom therapy trials will grab headlines but prove nothing yet | 71% | ⏳ Pending |
| 2026-08-14 | Early signs that mushrooms help addiction and PTSD together, coming soon | 66% | ⏳ Pending |
| 2026-08-14 | A big news outlet will investigate ibogaine's heart risks before year-end | 65% | ⏳ Pending |
| 2026-08-14 | No big pharma will spend $100M or more on a psychedelic company yet | 64% | ⏳ Pending |
| 2026-08-13 | Under-skin ketamine study will report safety only, no approval impact | 74% | ⏳ Pending |
| 2026-08-13 | Scientists will publicly criticize the under-skin ketamine study's design flaws | 68% | ⏳ Pending |
| 2026-08-13 | Psilocybin anxiety trial shows promise, triggering a larger follow-up study | 66% | ⏳ Pending |
| 2026-08-13 | No separate psychedelic bill gets a full House vote this year | 65% | ⏳ Pending |
| 2026-08-13 | Federal psychedelic reform stalls; states and a veterans defense bill are the only hope | 63% | ⏳ Pending |
| 2026-08-12 | Scientists will publicly criticize esketamine therapy study design | 74% | ⏳ Pending |
| 2026-08-12 | Experts will demand better esketamine study controls within 10 weeks | 73% | ⏳ Pending |
| 2026-08-12 | Esketamine study can't separate drug from therapy — critics incoming | 72% | ⏳ Pending |
| 2026-08-12 | Psilocybin for anxiety and alcohol problems won't reach FDA talks soon | 70% | ⏳ Pending |
| 2026-08-12 | Ibogaine stays offshore and out of DEA reach for now | 70% | ⏳ Pending |
| 2026-08-11 | Federal drug agency won't review psilocybin or ibogaine status this quarter | 72% | ⏳ Pending |
| 2026-08-11 | COMPASS Pathways stock price likely stays flat through mid-October | 70% | ⏳ Pending |
| 2026-08-11 | COMPASS Pathways stock unlikely to spike or crash before September 10 | 70% | ⏳ Pending |
| 2026-08-11 | Scientists will publicly criticize the design of a new ketamine therapy study | 68% | ⏳ Pending |
| 2026-08-11 | Experts will question a ketamine therapy pilot study's methods within weeks | 66% | ⏳ Pending |
| 2026-08-10 | COMPASS's two-dose psilocybin trial shows better results but with a catch | 70% | ⏳ Pending |
| 2026-08-10 | Two-dose psilocybin trial result is the biggest near-term test for the whole industry | 68% | ⏳ Pending |
| 2026-08-10 | COMPASS stock will swing wildly — at least 20% — on trial results day | 68% | ⏳ Pending |
| 2026-08-10 | COMPASS's press release will oversell the results — and someone will fact-check it | 66% | ⏳ Pending |
| 2026-08-10 | Bad trial results will crash COMPASS stock — possibly 20% or more in one day | 62% | ⏳ Pending |
| 2026-08-09 | US drug cops will keep toad venom tightly banned, full stop | 70% | ⏳ Pending |
| 2026-08-09 | Only one psychedelic company's stock will swing big this year | 62% | ⏳ Pending |
| 2026-08-09 | Science still can't back up toad venom's big therapeutic claims | 62% | ⏳ Pending |
| 2026-08-09 | A meditation brain study will spark debate and fuel psychedelic theories | 60% | ⏳ Pending |
| 2026-08-09 | Wall Street will pitch psychedelics as a conservative-friendly market opportunity | 60% | ⏳ Pending |
| 2026-08-08 | Public hospital psilocybin depression trial hits its main goal | 62% | ⏳ Pending |
| 2026-08-08 | Both parties back a bill giving veterans access to psychedelic therapy | 62% | ⏳ Pending |
| 2026-08-08 | MindMed announces the specific news behind its sudden stock jump | 60% | ⏳ Pending |
| 2026-08-08 | A formal bipartisan veteran psychedelic amendment enters the defense bill | 60% | ⏳ Pending |
| 2026-08-08 | MindMed reveals the real reason behind its mysterious stock surge | 60% | ⏳ Pending |
| 2026-08-07 | Scientists publish proof psilocybin rewires the brain fast in alcohol study | 72% | ⏳ Pending |
| 2026-08-07 | Scientists publish proof psilocybin rewires the brain fast in alcohol study | 71% | ⏳ Pending |
| 2026-08-07 | Scientists will publish a clear explanation for why psychedelics work so fast | 71% | ⏳ Pending |
| 2026-08-07 | Psilocybin studies for autism and eating disorders won't show full results yet | 70% | ⏳ Pending |
| 2026-08-07 | The DEA will not loosen rules on psilocybin supply for researchers | 68% | ⏳ Pending |
| 2026-08-06 | Psilocybin autism-depression study will only report early safety data | 68% | ⏳ Pending |
| 2026-08-06 | New 'growth CEO' hire at psychedelic biotech signals a dilutive fundraise is coming | 66% | ⏳ Pending |
| 2026-08-06 | Regulators will warn about ibogaine heart risks, not open a new access path | 66% | ⏳ Pending |
| 2026-08-06 | Big CEO hire was cover for a dilutive fundraise all along | 63% | ⏳ Pending |
| 2026-08-06 | ACP-211 depression drug trial will hit a positive milestone within 12 weeks | 62% | ⏳ Pending |
| 2026-08-05 | No solid ibogaine study will confirm ketamine-abstinence finding soon | 70% | ⏳ Pending |
| 2026-08-05 | No official FDA meeting scheduled for TRP-8803 drug program anytime soon | 68% | ⏳ Pending |
| 2026-08-05 | No standalone psychedelic law will get a full Congress vote this fall | 66% | ⏳ Pending |
| 2026-08-05 | Ibogaine case sparks interest but no rigorous human study follows quickly | 64% | ⏳ Pending |
| 2026-08-05 | Small psychedelic stock's big price jump will likely fade fast | 64% | ⏳ Pending |
| 2026-08-04 | Ibogaine heart-risk rules block any new ketamine-addiction trial starting | 72% | ⏳ Pending |
| 2026-08-04 | COMPASS Pathways' psilocybin drug program hits no major US regulatory milestone | 70% | ⏳ Pending |
| 2026-08-04 | One ibogaine case report won't change US drug laws or expand legal access | 70% | ⏳ Pending |
| 2026-08-04 | No rigorous science on how ibogaine and ketamine interact will emerge soon | 68% | ⏳ Pending |
| 2026-08-04 | COMPASS stock likely falls back and no psychedelic company mergers happen soon | 63% | ⏳ Pending |
| 2026-08-03 | US drug regulator won't publish special psilocybin rules by year-end | 70% | ⏳ Pending |
| 2026-08-03 | Early psilocybin trials report safety data only, not proof it works | 68% | ⏳ Pending |
| 2026-08-03 | Veterans bill won't give vets real psychedelic access this year | 66% | ⏳ Pending |
| 2026-08-03 | MindMed will make a major company announcement within six weeks | 64% | ⏳ Pending |
| 2026-08-03 | Retracted psychedelic study will trigger official misconduct investigation within eight weeks | 63% | ⏳ Pending |
| 2026-08-02 | A private deal memo won't budge psychedelic stock prices in August | 72% | ⏳ Pending |
| 2026-08-02 | Two key psychedelic stocks will likely stay flat through August | 70% | ⏳ Pending |
| 2026-08-02 | A psychedelic medicine bill will get more supporters but no vote before fall | 66% | ⏳ Pending |
| 2026-08-02 | Veterans psychedelic pilot results will show up in Congress within 8 weeks | 66% | ⏳ Pending |
| 2026-08-02 | A major veterans group will back psychedelic medicine access within 6 weeks | 63% | ⏳ Pending |
| 2026-08-01 | The US drug agency won't review psilocybin's legal status soon | 75% | ⏳ Pending |
| 2026-08-01 | Veteran psilocybin study gets political buzz but no FDA response | 72% | ⏳ Pending |
| 2026-08-01 | Compass Pathways stock likely stays below $12.50 through September | 72% | ⏳ Pending |
| 2026-08-01 | No FDA expert panel meeting for Compass's depression drug before mid-October | 70% | ⏳ Pending |
| 2026-08-01 | Veteran psilocybin study will face public scientific criticism within weeks | 68% | ⏳ Pending |
| 2026-07-31 | Veterans' mushroom study won't trigger any FDA review meetings this year | 80% | ⏳ Pending |
| 2026-07-31 | Veterans' psilocybin study will inspire advocates but won't move regulators in 2026 | 76% | ⏳ Pending |
| 2026-07-31 | Veterans' psilocybin study won't change DEA research rules or drug supply access in 2026 | 75% | ⏳ Pending |
| 2026-07-31 | COMPASS Pathways stock price likely stays flat through mid-September 2026 | 74% | ⏳ Pending |
| 2026-07-31 | No standalone psilocybin bill will get a full congressional vote in 2026 | 72% | ⏳ Pending |
| 2026-07-30 | COMPASS stock stays flat until big trial results arrive | 70% | ⏳ Pending |
| 2026-07-30 | US drug regulators won't publish new psychedelic rules before late 2026 | 68% | ⏳ Pending |
| 2026-07-30 | Brain scan study shows drug effect but can't link it to patient improvement | 62% | ⏳ Pending |
| 2026-07-30 | Congress will likely try to expand psychedelic access for veterans this fall | 62% | ⏳ Pending |
| 2026-07-30 | Brain scan study shows drug effect but can't link it to patient improvement | 62% | ⏳ Pending |
| 2026-07-29 | Congress skips standalone psychedelic bill; veterans bill sneaks through defense budget | 68% | ⏳ Pending |
| 2026-07-29 | FDA raises red flags about how psychedelic drug trials are designed | 66% | ⏳ Pending |
| 2026-07-29 | States keep pushing psychedelic laws while Congress stays on the sidelines | 65% | ⏳ Pending |
| 2026-07-29 | New research paper on psychedelic trial flaws sparks major scientific debate | 64% | ⏳ Pending |
| 2026-07-29 | Early psilocybin OCD study shows promise, triggering a new follow-up trial | 64% | ⏳ Pending |
| 2026-07-28 | No big psychedelic company buyouts happen in the next two months | 66% | ⏳ Pending |
| 2026-07-28 | Veteran psychedelic therapy progress sneaks through the defense budget bill | 63% | ⏳ Pending |
| 2026-07-28 | Veteran psychedelic access advances through budget bills, not the Turning Point Act | 62% | ⏳ Pending |
| 2026-07-28 | Veteran psychedelic access moves via budget bills, not named standalone laws | 62% | ⏳ Pending |
| 2026-07-28 | A new research paper on flawed psychedelic trial design becomes widely influential | 60% | ⏳ Pending |
| 2026-07-27 | MDMA therapy company won't reapply for approval this year | 68% | ⏳ Pending |
| 2026-07-27 | Exciting stem cell depression study sparks academic buzz but changes nothing for patients | 62% | ⏳ Pending |
| 2026-07-27 | MindMed stock jump hints at big company news coming soon | 62% | ⏳ Pending |
| 2026-07-27 | MindMed will announce major news about its anxiety drug within 8 weeks | 62% | ⏳ Pending |
| 2026-07-27 | New depression research sparks follow-up studies but won't change any treatments | 62% | ⏳ Pending |
| 2026-07-26 | No DEA drug rescheduling for ibogaine or psychedelics this quarter | 72% | ⏳ Pending |
| 2026-07-26 | FDA won't give ibogaine a special approval status this quarter | 70% | ⏳ Pending |
| 2026-07-26 | The 'Trump fast-tracks ibogaine' story is hype — no real action follows | 67% | ⏳ Pending |
| 2026-07-26 | Scientists will publicly challenge a key ketamine brain-study paper within five months | 66% | ⏳ Pending |
| 2026-07-26 | A government-funded brain-stimulation deal helps one company, not the whole psychedelic sector | 63% | ⏳ Pending |
| 2026-07-25 | Major news outlet will question ibogaine's heart risks or political push | 70% | ⏳ Pending |
| 2026-07-25 | Veteran groups will formally demand ibogaine access from VA or Congress | 68% | ⏳ Pending |
| 2026-07-25 | Regulators or scientists will formally flag ibogaine's dangerous heart side effects | 63% | ⏳ Pending |
| 2026-07-25 | A US state will fund or propose an ibogaine program for veterans | 60% | ⏳ Pending |
| 2026-07-25 | Lab study will show depression changes how brain cells respond to antidepressants over time | 55% | ⏳ Pending |
| 2026-07-24 | Congress won't touch psychedelic drug laws before summer break | 78% | ⏳ Pending |
| 2026-07-24 | No psychedelic therapy access gets added to any current bill before summer | 75% | ⏳ Pending |
| 2026-07-24 | Brain scan finding from ketamine study won't be confirmed in 12 weeks | 70% | ⏳ Pending |
| 2026-07-24 | Scientists will publicly push back on 'mushrooms rewire the brain' headlines | 67% | ⏳ Pending |
| 2026-07-24 | Researchers will publicly criticize the small size of the ketamine brain study | 66% | ⏳ Pending |
| 2026-07-23 | No psychedelic becomes federally legal in 2026 | 85% | ⏳ Pending |
| 2026-07-23 | Brain study headlines will wildly overstate what the science actually shows | 82% | ⏳ Pending |
| 2026-07-23 | Federal law on psychedelics won't change at all in 2026 | 81% | ⏳ Pending |
| 2026-07-23 | The FDA won't approve any classic psychedelic as a medicine in 2026 | 80% | ⏳ Pending |
| 2026-07-23 | Psilocybin brain research will be hyped beyond what it proved | 79% | ⏳ Pending |
| 2026-07-22 | Psilocybin and MDMA stay federally illegal until at least 2028 | 75% | ⏳ Pending |
| 2026-07-22 | Scientists learn more about how psychedelics work than patients can legally access | 74% | ⏳ Pending |
| 2026-07-22 | FDA will require another MDMA study before approving it as a medicine | 74% | ⏳ Pending |
| 2026-07-22 | Lab discoveries about psychedelics far outpace actual approved treatments through 2027 | 74% | ⏳ Pending |
| 2026-07-22 | Psilocybin and MDMA remain federally illegal through at least 2028 | 73% | ⏳ Pending |
| 2026-07-21 | No psychedelic drug will get US approval in the next month | 97% | ⏳ Pending |
| 2026-07-21 | Federal law on psychedelics won't change in the next three months | 93% | ⏳ Pending |
| 2026-07-21 | Congress won't pass a standalone law to legalize psychedelic research in a year | 85% | ⏳ Pending |
| 2026-07-21 | A recent stock rally in psychedelic companies will likely fade by mid-September | 60% | ⏳ Pending |
| 2026-07-21 | At least one major psilocybin depression study will show clear positive results this year | 60% | ⏳ Pending |
| 2026-07-20 | US drug agency won't move to reschedule psilocybin or MDMA soon | 85% | ⏳ Pending |
| 2026-07-20 | Psychedelic stock fund unlikely to swing 25% in either direction | 78% | ⏳ Pending |
| 2026-07-20 | Psilocybin and MDMA stay fully federally illegal through end of 2026 | 74% | ⏳ Pending |
| 2026-07-20 | Psychedelic biotech stocks will stay flat without a major trial result | 72% | ⏳ Pending |
| 2026-07-20 | Congress will not make psilocybin or MDMA federally legal by early 2027 | 71% | ⏳ Pending |
| 2026-07-19 | The DEA will keep psychedelics fully illegal in 2026 | 78% | ⏳ Pending |
| 2026-07-19 | Federal law on psychedelics stays unchanged through 2026 | 77% | ⏳ Pending |
| 2026-07-19 | No broad federal legalization, but veterans may get limited psychedelic access | 76% | ⏳ Pending |
| 2026-07-19 | Congress won't touch psychedelic drug laws at all in 2026 | 75% | ⏳ Pending |
| 2026-07-19 | MDMA therapy for PTSD won't get FDA approval in 2026 | 74% | ⏳ Pending |
| 2026-07-18 | MDMA therapy for trauma unlikely to get US approval before mid-2027 | 75% | ⏳ Pending |
| 2026-07-18 | MDMA trauma therapy approval still years away, experts agree | 73% | ⏳ Pending |
| 2026-07-18 | Big investors won't pour money into psychedelic companies until 2027 | 72% | ⏳ Pending |
| 2026-07-18 | MDMA trauma treatment needs stronger science before US approval | 72% | ⏳ Pending |
| 2026-07-18 | Psychedelic drug reform stalls in Congress; small veteran programs may survive | 70% | ⏳ Pending |
| 2026-07-17 | No psychedelic drug gets full US approval before August 2026 | 97% | ⏳ Pending |
| 2026-07-17 | MDMA and psilocybin stay in the most restricted drug category through mid-2026 | 90% | ⏳ Pending |
| 2026-07-17 | Psilocybin and MDMA won't get full US drug approval in all of 2026 | 85% | ⏳ Pending |
| 2026-07-17 | US Congress won't legalize or federally approve psychedelics in 2026 | 83% | ⏳ Pending |
| 2026-07-17 | Compass Pathways stock likely stays under $20 through September 2026 | 72% | ⏳ Pending |
| 2026-07-16 | Psilocybin, MDMA, and LSD stay illegal federally through 2026 | 74% | ⏳ Pending |
| 2026-07-16 | Congress won't hold a vote on legalizing psychedelics federally by 2026 | 72% | ⏳ Pending |
| 2026-07-16 | Government advisors will officially question how long MDMA therapy effects last | 70% | ⏳ Pending |
| 2026-07-16 | FDA may approve MDMA therapy but with tight controls on who can give it | 68% | ⏳ Pending |
| 2026-07-16 | MDMA therapy for PTSD could get FDA approval within the next year | 55% | ⏳ Pending |
| 2026-07-15 | Psilocybin for bipolar II needs much stronger safety data first | 75% | ⏳ Pending |
| 2026-07-15 | Congress won't vote on making psilocybin legal this year | 72% | ⏳ Pending |
| 2026-07-15 | Psychedelic company stocks won't see a lasting recovery this year | 72% | ⏳ Pending |
| 2026-07-15 | Psychedelic company stocks won't see a lasting recovery this year | 70% | ⏳ Pending |
| 2026-07-15 | MDMA therapy for PTSD needs a do-over before the FDA will approve it | 70% | ⏳ Pending |
| 2026-07-14 | No psychedelic therapy will get US government approval by 2026 | 82% | ⏳ Pending |
| 2026-07-14 | Psychedelics stay illegal federally through at least mid-2026 | 80% | ⏳ Pending |
| 2026-07-14 | Psilocybin and MDMA will remain in the most restricted drug category through 2026 | 80% | ⏳ Pending |
| 2026-07-14 | No solid clinical trial results for psilocybin in bipolar or eating disorders yet | 75% | ⏳ Pending |
| 2026-07-14 | Congress will fund only military veteran psychedelic research, nothing broader | 72% | ⏳ Pending |
| 2026-07-13 | No US government approval for psilocybin therapy before August 2026 | 95% | ⏳ Pending |
| 2026-07-13 | Psilocybin and MDMA stay in the most restricted drug category through October 2026 | 90% | ⏳ Pending |
| 2026-07-13 | Psilocybin and MDMA remain fully illegal federally through end of 2026 | 82% | ⏳ Pending |
| 2026-07-13 | Congress funds psychedelic research for veterans but passes no broad drug law in 2026 | 80% | ⏳ Pending |
| 2026-07-13 | Psychedelic company stock prices stay flat without major clinical trial results by August 2026 | 70% | ⏳ Pending |
| 2026-07-12 | Magic mushrooms and MDMA stay federally illegal through 2026 | 85% | ⏳ Pending |
| 2026-07-12 | The DEA won't budge on psilocybin or MDMA rules in 2026 | 85% | ⏳ Pending |
| 2026-07-12 | Experts agree: no federal drug status change in 2026 | 84% | ⏳ Pending |
| 2026-07-12 | Congress won't hold a full vote on psychedelic drug rescheduling in 2026 | 80% | ⏳ Pending |
| 2026-07-12 | FDA likely to call an expert panel review of COMPASS's psilocybin therapy | 74% | ⏳ Pending |
| 2026-07-11 | Psilocybin stays illegal federally through August 2026 | 97% | ⏳ Pending |
| 2026-07-11 | Psilocybin stays a federally banned substance all through 2026 | 90% | ⏳ Pending |
| 2026-07-11 | FDA will demand proof psilocybin benefits last before approving it | 72% | ⏳ Pending |
| 2026-07-11 | A government-backed psychedelic program for veterans launches within a year | 70% | ⏳ Pending |
| 2026-07-11 | COMPASS Pathways stock: will it stay above $5 in August 2026? | 55% | ✓ Came true |
| 2026-07-10 | Psychedelic company stocks will stay low through late 2026 | 75% | ⏳ Pending |
| 2026-07-10 | The FDA will demand more proof before approving MDMA therapy | 74% | ⏳ Pending |
| 2026-07-10 | Any approved psychedelic drug will come with strict access controls | 73% | ⏳ Pending |
| 2026-07-10 | Congress won't pass a psychedelic law in 2026, but states will keep moving | 72% | ⏳ Pending |
| 2026-07-10 | No nationwide psychedelic law will pass in 2026 | 72% | ⏳ Pending |
| 2026-07-09 | Psychedelics stay illegal federally until a drug gets full approval | 78% | ⏳ Pending |
| 2026-07-09 | Congress won't legalize psychedelics in 2026 — small veteran carve-outs only | 75% | ⏳ Pending |
| 2026-07-09 | No federal psychedelic legalization bill passes in 2026 | 74% | ⏳ Pending |
| 2026-07-09 | Two new psychedelic trials for alcohol addiction or postpartum depression launch in 2026 | 72% | ⏳ Pending |
| 2026-07-09 | Psilocybin and ibogaine won't leapfrog MDMA in the FDA approval race in 2026 | 70% | ⏳ Pending |
| 2026-07-08 | The DEA will not change psychedelic drug rules in 2026 | 80% | ⏳ Pending |
| 2026-07-08 | No psychedelic drug gets federally approved or reclassified in 2026 | 79% | ⏳ Pending |
| 2026-07-08 | MDMA therapy will not get FDA approval in 2026 | 78% | ⏳ Pending |
| 2026-07-08 | One drug trial result will drive the whole psychedelic sector's value in 2026 | 70% | ⏳ Pending |
| 2026-07-08 | Congress will fund psychedelic research in 2026, but not legalize access | 70% | ⏳ Pending |
| 2026-07-07 | New law opens psychedelic access without changing drug approval rules | 70% | ⏳ Pending |
| 2026-07-07 | Psilocybin and MDMA stay in the 'most restricted' drug category for now | 70% | ⏳ Pending |
| 2026-07-07 | Federal drug rescheduling for psychedelics won't happen in 18 months | 69% | ⏳ Pending |
| 2026-07-07 | Veterans may gain special psychedelic access without any rescheduling | 68% | ⏳ Pending |
| 2026-07-07 | A promising psychedelic depression drug moves to large-scale testing | 68% | ⏳ Pending |
| 2026-07-06 | Psilocybin and ibogaine stay in the most restricted drug category | 85% | ⏳ Pending |
| 2026-07-06 | Federal government won't reclassify psychedelics anytime soon | 82% | ⏳ Pending |
| 2026-07-06 | Psychedelic company stock prices stay flat or keep falling through early 2027 | 80% | ⏳ Pending |
| 2026-07-06 | No new psychedelic drug gets full federal approval in the next year | 78% | ⏳ Pending |
| 2026-07-06 | Congress won't pass any law expanding psychedelic access this year | 78% | ⏳ Pending |
| 2026-07-05 | No psychedelic therapy gets US government approval before August 2026 | 97% | ⏳ Pending |
| 2026-07-05 | US Congress will not pass a law changing psychedelic drug status in 2026 | 85% | ⏳ Pending |
| 2026-07-05 | The US drug enforcement agency won't reclassify psychedelics in 2026 | 82% | ⏳ Pending |
| 2026-07-05 | A veterans-focused psychedelic research bill gets a meaningful vote in Congress within a year | 60% | ⏳ Pending |
| 2026-07-05 | A new US study on ibogaine or a related compound registers publicly by August 2026 | 40% | ⏳ Pending |
| 2026-07-04 | Ibogaine will not get US drug approval by August 2026 | 98% | ⏳ Pending |
| 2026-07-04 | US government won't officially loosen drug rules for psilocybin, MDMA, or ibogaine by August 2026 | 97% | ⏳ Pending |
| 2026-07-04 | Ibogaine stays unapproved in the US through fall 2026; safer versions are being studied | 95% | ⏳ Pending |
| 2026-07-04 | Psilocybin, MDMA, and ibogaine stay federally illegal through all of 2026 | 85% | ⏳ Pending |
| 2026-07-04 | US veterans will get documented access to psychedelic treatment before federal laws change | 70% | ⏳ Pending |
| 2026-07-03 | No psychedelic therapy will get US drug approval before August 2026 | 97% | ⏳ Pending |
| 2026-07-03 | Psilocybin and MDMA will stay in the most restricted drug category all of 2026 | 90% | ⏳ Pending |
| 2026-07-03 | A ketamine or psychedelic clinic scandal will make national US news by August 2026 | 65% | ⏳ Pending |
| 2026-07-03 | A key clinical trial result will send a psychedelic company's stock up or down 25% in one day | 62% | ⏳ Pending |
| 2026-07-03 | The FDA will formally act on a psilocybin-for-depression drug application by mid-2027 | 55% | ⏳ Pending |
| 2026-07-02 | Any approved psychedelic drug will require special certified clinics | 82% | ⏳ Pending |
| 2026-07-02 | Psychedelics stay illegal federally except in approved medical settings | 78% | ⏳ Pending |
| 2026-07-02 | Approved psychedelics will require supervised clinics, not free access | 76% | ⏳ Pending |
| 2026-07-02 | No law to loosen federal psychedelic restrictions will pass in 2026 | 75% | ⏳ Pending |
| 2026-07-02 | At least two small psychedelic companies will merge or get bought out by early 2027 | 75% | ⏳ Pending |
| 2026-07-01 | Psilocybin stays on the most restricted drug list for now | 78% | ⏳ Pending |
| 2026-07-01 | Psilocybin stays on the most restricted drug list for now | 75% | ⏳ Pending |
| 2026-07-01 | The FDA won't approve a psilocybin drug within 18 months | 75% | ⏳ Pending |
| 2026-07-01 | MDMA's FDA decision will swing the whole psychedelic market 25% either way | 72% | ⏳ Pending |
| 2026-07-01 | Brain scan findings hold up, but specific disease cure claims need fixing | 72% | ⏳ Pending |
| 2026-06-30 | No psychedelic drug gets full US approval in 2026 | 76% | ⏳ Pending |
| 2026-06-30 | Magic mushrooms and LSD stay fully illegal federally through 2026 | 72% | ⏳ Pending |
| 2026-06-30 | Psychedelic company stocks mostly stay flat through mid-2026 | 71% | ⏳ Pending |
| 2026-06-30 | Strong trial results for psilocybin treating addiction published by mid-2027 | 68% | ⏳ Pending |
| 2026-06-29 | Psilocybin and MDMA stay illegal federally through 2026 | 78% | ⏳ Pending |
| 2026-06-29 | No federal legalization change for psychedelics in 2026 | 77% | ⏳ Pending |
| 2026-06-29 | Congress won't legalize psilocybin in 2026, but may fund veteran programs | 75% | ⏳ Pending |
| 2026-06-29 | FDA will not approve psilocybin in 2026; MDMA needs more proof first | 74% | ⏳ Pending |
| 2026-06-29 | Psychedelic company stock prices will stay flat through mid-2026 | 72% | ⏳ Pending |
| 2026-06-28 | A major depression drug trial posts promising results in 2026 | 80% | ⏳ Pending |
| 2026-06-28 | Any approved psychedelic drug will come with strict ongoing safety rules | 78% | ⏳ Pending |
| 2026-06-28 | Psychedelics stay in the most restricted drug category for at least another year | 75% | ⏳ Pending |
| 2026-06-28 | Depression trial results look promising but work better for some patients than others | 74% | ⏳ Pending |
| 2026-06-28 | Federal law on psychedelics will not change in the next 12 months | 74% | ⏳ Pending |
| 2026-06-27 | No psychedelic therapy will get US government approval in 2026 | 85% | ⏳ Pending |
| 2026-06-27 | The US government won't reclassify mushrooms or MDMA in 2026 | 82% | ⏳ Pending |
| 2026-06-27 | One company's mushroom drug trial results will cause a massive stock swing | 76% | ⏳ Pending |
| 2026-06-27 | The big psilocybin trial will likely show the drug actually works | 70% | ⏳ Pending |
| 2026-06-27 | Experts will publicly question whether the trial results are trustworthy | 68% | ⏳ Pending |
| 2026-06-26 | Psilocybin and MDMA stay illegal at the federal level in 2026 | 80% | ⏳ Pending |
| 2026-06-26 | Federal drug law won't change, but veterans may get easier research access | 79% | ⏳ Pending |
| 2026-06-26 | Scientists will zero in on how psychedelics reduce brain inflammation and rewire connections | 75% | ⏳ Pending |
| 2026-06-26 | No psychedelic drug will get full FDA approval in 2026, but a strict conditional path may be proposed | 70% | ⏳ Pending |
| 2026-06-26 | Psychedelic stock gains will likely reverse fast without hard clinical trial data | 66% | ⏳ Pending |
| 2026-06-25 | Ketamine drugs will get US approval before MDMA or psilocybin | 74% | ⏳ Pending |
| 2026-06-25 | Magic mushrooms will stay federally illegal for at least two more years | 72% | ⏳ Pending |
| 2026-06-25 | Congress won't legalize magic mushrooms — small veteran bills are the best case | 72% | ⏳ Pending |
| 2026-06-25 | Any approved psychedelic drug will come with very strict safety controls | 72% | ⏳ Pending |
| 2026-06-25 | Approved psychedelics will face tight government controls, not open access | 70% | ⏳ Pending |
| 2026-06-24 | The DEA won't change psilocybin or MDMA's legal status in 2026 | 78% | ⏳ Pending |
| 2026-06-24 | Congress won't pass a federal psychedelic drug reform law in 2026 | 76% | ⏳ Pending |
| 2026-06-24 | If MDMA gets approved for PTSD treatment, it will come with strict conditions attached | 74% | ⏳ Pending |
| 2026-06-24 | Psilocybin won't get FDA approval as a medicine in 2026 | 73% | ⏳ Pending |
| 2026-06-24 | Scientists will publicly push back on overhyped psychedelic treatment claims | 70% | ⏳ Pending |
| 2026-06-23 | MDMA stays illegal federally even if the FDA approves it | 78% | ⏳ Pending |
| 2026-06-23 | MDMA stays in the most restricted drug category through 2026 | 76% | ⏳ Pending |
| 2026-06-23 | No federal law legalizing psychedelics in 2026 — states lead the way | 75% | ⏳ Pending |
| 2026-06-23 | FDA will attach strict conditions to any MDMA approval — not a free pass | 74% | ⏳ Pending |
| 2026-06-23 | Any MDMA approval comes with tight restrictions and required follow-up studies | 72% | ⏳ Pending |
| 2026-06-22 | Psilocybin and MDMA stay on the US banned list through 2025 | 85% | ⏳ Pending |
| 2026-06-22 | US Congress will not pass a law legalizing these drugs by 2025 | 80% | ⏳ Pending |
| 2026-06-22 | A key flaw in psychedelic drug trials will keep making headlines | 80% | ⏳ Pending |
| 2026-06-22 | MDMA therapy for trauma will not get US approval by end of 2025 | 78% | ⏳ Pending |
| 2026-06-22 | Any approved psychedelic therapy must happen in a monitored clinic | 74% | ⏳ Pending |
| 2026-06-21 | No psychedelic drug will get US approval in 2026 | 74% | ⏳ Pending |
| 2026-06-21 | Psychedelics will stay in the most restricted drug category through 2026 | 74% | ⏳ Pending |
| 2026-06-21 | Congress will only fund small veteran-focused psychedelic pilot programs | 70% | ⏳ Pending |
| 2026-06-21 | No psychedelic treatment approved using only real-world patient data by mid-2027 | 69% | ⏳ Pending |
| 2026-06-21 | DEA will crack down on at-home ketamine prescribed over video call | 68% | ⏳ Pending |
| 2026-06-20 | The DEA will not change psilocybin or MDMA's illegal status this year | 72% | ⏳ Pending |
| 2026-06-20 | Congress will not vote on rescheduling psychedelics within 12 months | 71% | ⏳ Pending |
| 2026-06-20 | The FDA will add major conditions before approving MDMA as a medicine | 70% | ⏳ Pending |
| 2026-06-20 | A psychedelic company's stock will jump or crash more than 20% in a single day | 70% | ⏳ Pending |
| 2026-06-20 | Science is advancing faster than clinics can safely standardize psychedelic treatments | 68% | ⏳ Pending |
| 2026-06-19 | Drug approval rules and scheduling delays will limit who gets access | 74% | ⏳ Pending |
| 2026-06-19 | A psychedelic drug could get approved and reach patients faster than expected | 74% | ⏳ Pending |
| 2026-06-19 | The DEA's separate drug reclassification will delay real patient access by at least six months | 74% | ⏳ Pending |
| 2026-06-19 | A psychedelic medicine will likely get FDA approval within the next year | 72% | ⏳ Pending |
| 2026-06-19 | FDA approval of a psychedelic could spark real political action in Congress | 72% | ⏳ Pending |
| 2026-06-18 | Approved psychedelic drugs will only be available at licensed, supervised clinics | 82% | ⏳ Pending |
| 2026-06-18 | Magic mushrooms will stay federally illegal all year, no matter what | 80% | ⏳ Pending |
| 2026-06-18 | Psilocybin remains federally illegal this year; federal approval and scheduling are separate slow processes | 79% | ⏳ Pending |
| 2026-06-18 | DEA won't change psilocybin's legal status even if the FDA approves it for medicine | 78% | ⏳ Pending |
| 2026-06-18 | If approved, psychedelic treatments will only reach a small fraction of patients at first | 75% | ⏳ Pending |
| 2026-06-17 | Psychedelics stay illegal at the federal level through 2026 | 85% | ⏳ Pending |
| 2026-06-17 | Congress won't pass a broad psychedelics law in 2026 | 82% | ⏳ Pending |
| 2026-06-17 | No psychedelic drug gets FDA approval in 2026 | 80% | ⏳ Pending |
| 2026-06-17 | A psychedelic stock's big one-day spike likely fades fast | 70% | ✗ Did not happen |
| 2026-06-17 | The dramatic Alzheimer's-psilocybin claim will likely get walked back | 68% | ✓ Came true |
| 2026-06-16 | MDMA and psilocybin stay federally illegal through 2027 | 78% | ⏳ Pending |
| 2026-06-16 | FDA will demand another full MDMA trial before approving it | 72% | ⏳ Pending |
| 2026-06-16 | No reliable biological test for predicting psychedelic therapy success by 2027 | 70% | ⏳ Pending |
| 2026-06-16 | At least one more US state will open a legal psychedelic therapy program by mid-2027 | 65% | ⏳ Pending |
| 2026-06-15 | Psychedelics stay in the most restricted drug category until at least mid-2027 | 85% | ⏳ Pending |
| 2026-06-15 | No psychedelic drug will get FDA approval or a formal review meeting before late 2026 | 80% | ⏳ Pending |
| 2026-06-15 | Congress won't hold a full floor vote on any psychedelic-focused bill before fall 2026 | 80% | ⏳ Pending |
| 2026-06-15 | The FDA will not approve MDMA as a PTSD treatment before September 2026 | 78% | ⏳ Pending |
| 2026-06-15 | No human trial of psilocybin for brain injury recovery will start before mid-2027 | 72% | ⏳ Pending |
| 2026-06-14 | US drug regulator won't approve any psychedelic medicine in 2026 | 74% | ⏳ Pending |
| 2026-06-14 | Federal law on psychedelics will not change in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Congress will not pass any psychedelic law reform in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Lab discoveries about psychedelics will race ahead of real-world clinical proof in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Brain science on psychedelics will outrun human clinical proof in 2026 | 70% | ⏳ Pending |
| 2026-06-13 | Psilocybin and MDMA stay in the most restricted drug category through 2026 | 85% | ⏳ Pending |
| 2026-06-13 | No psychedelic drug gets full FDA approval in 2026 | 76% | ⏳ Pending |
| 2026-06-13 | Congress won't broadly legalize psychedelics in 2026 — only veterans get traction | 75% | ⏳ Pending |
| 2026-06-13 | Scientists publish major new findings on exactly how psilocybin works in the brain | 74% | ⏳ Pending |
| 2026-06-13 | Veterans will be the only group to win new psychedelic access laws by mid-2027 | 70% | ⏳ Pending |
| 2026-06-12 | Congress won't change psilocybin or MDMA drug laws by 2026 | 80% | ⏳ Pending |
| 2026-06-12 | Psilocybin and dementia headlines will mislead — then get corrected | 72% | ⏳ Pending |
| 2026-06-12 | US drug cops will crack down on at least two ketamine telehealth companies | 62% | ⏳ Pending |
| 2026-06-12 | FDA will issue an official warning about at-home and compounded ketamine | 58% | ⏳ Pending |
| 2026-06-11 | Psychedelic drug reform bills won't get a real vote in 2026 | 80% | ⏳ Pending |
| 2026-06-11 | A major news outlet will expose ketamine clinic bad practices | 74% | ⏳ Pending |
| 2026-06-11 | Veterans may get ibogaine treatment funding tucked into military bill | 68% | ⏳ Pending |
| 2026-06-11 | The DEA will crack down on at least one ketamine provider | 65% | ⏳ Pending |
| 2026-06-11 | Two more VA hospitals may launch psilocybin therapy programs | 60% | ⏳ Pending |
| 2026-06-10 | Psilocybin, MDMA, and ibogaine stay fully illegal federally in 2026 | 91% | ⏳ Pending |
| 2026-06-10 | Congress will not vote on any bill to legalize or reschedule psychedelics in 2026 | 86% | ⏳ Pending |
| 2026-06-10 | A major news outlet will publish a hard-hitting investigation into ketamine clinics by early 2027 | 78% | ⏳ Pending |
| 2026-06-10 | US regulators will crack down on ketamine prescribing via telehealth by early 2027 | 74% | ⏳ Pending |
| 2026-06-10 | The DEA will publicly warn that federal drug law overrides state ibogaine programs in 2026 | 70% | ⏳ Pending |
| 2026-06-09 | Patient Choice Act won't pass Congress before January 2027 | 81% | ⏳ Pending |
| 2026-06-09 | DEA will delay any ibogaine research rule by at least 12 months | 77% | ⏳ Pending |
| 2026-06-09 | Compass Pathways stock drops below $9.50 before September 2026 | 74% | ⏳ Pending |
| 2026-06-09 | Ketamine clinics will outperform biotech index through end of 2026 | 73% | ⏳ Pending |
| 2026-06-09 | FDA warns against using single anecdotes as proof of psilocybin cures | 72% | ⏳ Pending |
| 2026-06-08 | No psychedelic drug moves out of Schedule I by end of 2026 | 80% | ⏳ Pending |
| 2026-06-08 | FDA-approved psychedelics require treatment centers and 6-hour monitoring | 76% | ⏳ Pending |
| 2026-06-08 | No published study proves psilocybin works for Alzheimer's before 2027 | 73% | ⏳ Pending |
| 2026-06-08 | Federal psychedelic research plan focuses on veterans and avoids MDMA | 72% | ⏳ Pending |
| 2026-06-08 | A large pharma company buys ketamine clinic infrastructure by September 2026 | 68% | ⏳ Pending |
| 2026-06-07 | Psilocybin and MDMA stay illegal under federal law through 2026 | 84% | ⏳ Pending |
| 2026-06-07 | Congress won't vote on psychedelic therapy bills before 2026 elections | 83% | ⏳ Pending |
| 2026-06-07 | FDA rejects MDMA-assisted therapy application, requests more data | 81% | ⏳ Pending |
| 2026-06-07 | DEA raids at least three ketamine clinics across different states | 72% | ⏳ Pending |
| 2026-06-07 | Two more states legalize psilocybin therapy by end of 2026 | 61% | ⏳ Pending |
| 2026-06-06 | Major US medical groups won't restrict ketamine for psychiatry based on rat studies by Oct 2026 | 78% | ⏳ Pending |
| 2026-06-06 | DEA will formally oppose psilocybin rescheduling before mid-2027, keeping it illegal | 75% | ⏳ Pending |
| 2026-06-06 | FDA will ask Mindmed for more MDMA-PTSD safety data, not approve or reject outright | 74% | ⏳ Pending |
| 2026-06-06 | Mindmed stock will beat ATAI and Compass on returns through September 2026 | 72% | ⏳ Pending |
| 2026-06-06 | ATAI and Compass will underperform the broader biotech sector through September 2026 | 71% | ⏳ Pending |
| 2026-06-05 | No psychedelic drug gets FDA approval in 2026 | 93% | ⏳ Pending |
| 2026-06-05 | Psilocybin won't get FDA approval before September 2028 | 81% | ⏳ Pending |
| 2026-06-05 | DEA will formally oppose psilocybin rescheduling by mid-2027 | 78% | ⏳ Pending |
| 2026-06-05 | Announced veteran psychedelic program enrolls zero patients by end-2026 | 74% | ⏳ Pending |
| 2026-06-05 | Major media outlets expose gap between veteran psychedelic promises and real access by end-2026 | 62% | ⏳ Pending |
| 2026-06-04 | Ketamine becomes the dominant billable psychedelic treatment by 2027 | 82% | ⏳ Pending |
| 2026-06-04 | DEA formally opposes ibogaine legal exemption in Congress | 74% | ⏳ Pending |
| 2026-06-04 | Scientists publish psilocybin brain-healing findings in top journals | 73% | ⏳ Pending |
| 2026-06-04 | FDA rejects MDMA therapy approval again in late 2026 | 72% | ⏳ Pending |
| 2026-06-04 | U.S. medical centers launch ketamine trials for suicidal youth | 71% | ⏳ Pending |
| 2026-06-03 | Mindmed stock will drop 8% within two weeks without major news | 80% | ⏳ Pending |
| 2026-06-03 | Federal psilocybin rescheduling will stall through 2027 | 78% | ⏳ Pending |
| 2026-06-03 | DEA will prosecute two ketamine clinics for illegal prescribing by 2026 | 72% | ⏳ Pending |
| 2026-06-03 | Ibogaine veteran treatment will enter defense bill by end of 2026 | 65% | ⏳ Pending |
| 2026-06-03 | Three medical schools will test ketamine plus add-on drugs by 2027 | 62% | ⏳ Pending |
| 2026-06-02 | No psychedelic drug will be rescheduled before March 2027 | 85% | ⏳ Pending |
| 2026-06-02 | Trump psychedelic fast-track order will produce zero regulatory changes by October 2026 | 80% | ⏳ Pending |
| 2026-06-02 | FDA rejects MDMA-PTSD approval, citing safety concerns by end of 2026 | 78% | ⏳ Pending |
| 2026-06-02 | Lykos Therapeutics shuts down, gets bought, or abandons MDMA program by 2026 | 74% | ⏳ Pending |
| 2026-06-02 | Three more states legalize psychedelics for veterans before 2027 | 72% | ⏳ Pending |
| 2026-06-01 | Psilocybin won't be rescheduled federally before 2028 | 82% | ⏳ Pending |
| 2026-06-01 | Three more states legalize psilocybin therapy or decriminalize before 2026 ends | 77% | ⏳ Pending |
| 2026-06-01 | Compass stock drops back to $12.80–$13.40 within one week | 74% | ✓ Came true |
| 2026-06-01 | DEA will publicly prosecute unlicensed retreat operators before September 2026 | 73% | ⏳ Pending |
| 2026-06-01 | U.S. lawmakers will frame psychedelic reform around veterans | 72% | ⏳ Pending |
| 2026-05-31 | DEA won't move on psilocybin or MDMA without FDA approval by end of 2026 | 88% | ⏳ Pending |
| 2026-05-31 | Congress won't vote on a psychedelic scheduling reform bill by end of 2026 | 85% | ⏳ Pending |
| 2026-05-31 | Three or more US states will propose veteran psychedelic therapy bills by end of 2026 | 81% | ⏳ Pending |
| 2026-05-31 | Compass Pathways stock will drop 5% within two weeks of May 31, 2026 | 79% | ✓ Came true |
| 2026-05-31 | Major news outlet will expose ketamine clinic safety or financial problems by fall 2026 | 72% | ⏳ Pending |
| 2026-05-30 | Psilocybin won't get rescheduled federally before January 2028 | 82% | ⏳ Pending |
| 2026-05-30 | MDMA won't get rescheduled federally before January 2028 | 79% | ⏳ Pending |
| 2026-05-30 | Compass Pathways stock will drop sharply after its recent spike | 77% | ✓ Came true |
| 2026-05-30 | DEA will block Congress from bypassing psilocybin scheduling rules | 72% | ⏳ Pending |
| 2026-05-30 | FDA will approve psilocybin research for broader depression, not just severe cases | 68% | ⏳ Pending |
| 2026-05-29 | No new state legislatures will legalize psychedelics by end of 2026 | 85% | ⏳ Pending |
| 2026-05-29 | Congress won't vote on federal psychedelic bills before November 2026 | 82% | ⏳ Pending |
| 2026-05-29 | DEA won't reschedule psilocybin before 2029 due to bureaucratic rules | 81% | ⏳ Pending |
| 2026-05-29 | Medicare won't pay for psilocybin therapy by end of 2028 | 78% | ⏳ Pending |
| 2026-05-29 | Compass Pathways stock will drop below $12 within 15 trading days | 76% | ✗ Did not happen |
| 2026-05-28 | MDMA won't get FDA approval in 2026, gets rejection letter instead | 73% | ⏳ Pending |
| 2026-05-28 | FDA will warn doctors about ketamine and suicidality risk before October 2026 | 72% | ⏳ Pending |
| 2026-05-28 | At least three states introduce ibogaine access bills for veterans by end of 2026 | 68% | ⏳ Pending |
| 2026-05-28 | MDMA PTSD study results published in major journal by September 2026 | 62% | ⏳ Pending |
| 2026-05-28 | Major news outlet investigates deaths at unregulated psychedelic retreats by September 2026 | 62% | ⏳ Pending |
| 2026-05-27 | MDMA therapy won't get FDA approval in 2026; company must start over | 82% | ⏳ Pending |
| 2026-05-27 | DEA will shut down at least two unregulated psychedelic retreat operators before September 2026 | 72% | ⏳ Pending |
| 2026-05-27 | At least one struggling psychedelic company will explore mergers before end of Q3 2026 | 71% | ⏳ Pending |
| 2026-05-27 | Congress will hold hearings on unregulated retreat safety after a publicized death | 68% | ⏳ Pending |
| 2026-05-27 | FDA will update ketamine therapy safety warnings or instructions for doctors by February 2027 | 64% | ⏳ Pending |
| 2026-05-26 | Veteran suicide data will feature in three major congressional budget speeches, linking ibogaine access to military ment | 81% | ⏳ Pending |
| 2026-05-26 | FDA will delay MDMA drug approval decision until mid-2027, requesting more cardiovascular safety data. | 79% | ⏳ Pending |
| 2026-05-26 | MDMA approval decision will slip to mid-2027 at earliest; 2026 approval unlikely. | 77% | ⏳ Pending |
| 2026-05-26 | Major news outlet will expose ketamine clinic safety failures before end of 2026. | 77% | ⏳ Pending |
| 2026-05-26 | DEA and FDA will pressure ketamine clinics with enforcement actions before early 2027. | 76% | ⏳ Pending |
| 2026-05-25 | FDA rejects MDMA therapy, demands another trial on blinding | 74% | ⏳ Pending |
| 2026-05-25 | Stanford's ibogaine study releases veteran outcomes by mid-2026 | 72% | ⏳ Pending |
| 2026-05-25 | A veteran testifies to Congress about their ibogaine treatment | 68% | ⏳ Pending |
| 2026-05-25 | Study published: MDMA blinding doesn't work in most trials | 65% | ⏳ Pending |
| 2026-05-25 | Major news outlet exposes Republican ties to psychedelic companies | 62% | ⏳ Pending |
| 2026-05-24 | Psilocybin stays illegal at federal level through 2028 | 85% | ⏳ Pending |
| 2026-05-24 | Only Oregon and Colorado approve legal psilocybin therapy by 2028 | 72% | ⏳ Pending |
| 2026-05-24 | Three major science journals publish psychedelic brain research in 2026 | 65% | ⏳ Pending |
| 2026-05-24 | A Phase 3 psychedelic trial hits its main goal by late 2026 | 62% | ⏳ Pending |
| 2026-05-24 | Congress funds psychedelic research for veterans by late 2026 | 58% | ⏳ Pending |
| 2026-05-23 | News outlet will badly distort a psilocybin study finding by August 2026 | 78% | ✗ Did not happen |
| 2026-05-23 | DEA will formally oppose letting military veterans access ibogaine | 76% | ⏳ Pending |
| 2026-05-23 | FDA will keep requiring heart monitoring for ibogaine trials through mid-2027 | 74% | ⏳ Pending |
| 2026-05-23 | Scientists will cite ibogaine brain plasticity finding in five new studies by May 2027 | 62% | ⏳ Pending |
| 2026-05-23 | Major news outlet will confuse psilocybin addiction research with recreational microdosing by July 2026 | 48% | ⏳ Pending |
| 2026-05-22 | FDA requires heart monitoring for ibogaine clinical trials by end of 2026 | 72% | ⏳ Pending |
| 2026-05-22 | Most new state psychedelic bills in 2026 target veterans with ibogaine | 68% | ⏳ Pending |
| 2026-05-22 | DEA will publicly charge at least two unlicensed psychedelic clinics by end of 2026 | 65% | ⏳ Pending |
| 2026-05-22 | No new psychedelic will get FDA fast-track approval status in 2026 | 61% | ⏳ Pending |
| 2026-05-22 | Two states will pass ibogaine access laws for veterans before July 2027 | 52% | ⏳ Pending |
| 2026-05-21 | FDA will require heart monitoring for ibogaine veteran programs by early 2027 | 72% | ⏳ Pending |
| 2026-05-21 | US ibogaine retreats marketing to veterans will grow 40% by mid-2027 | 63% | ⏳ Pending |
| 2026-05-21 | A death at an unregulated ibogaine retreat will trigger congressional investigation | 61% | ✓ Came true |
| 2026-05-21 | A major pharmaceutical company will acquire a psilocybin psychedelic firm by early 2027 | 52% | ⏳ Pending |
| 2026-05-21 | NIH will fund at least three ibogaine plasticity research grants within 18 months | 48% | ⏳ Pending |
| 2026-05-20 | Psilocybin stays illegal until at least end of 2027 | 88% | ⏳ Pending |
| 2026-05-20 | Major news will hype psilocybin addiction cure, then quietly correct | 78% | ✗ Did not happen |
| 2026-05-20 | Psilocybin NDA filed for depression treatment by late 2027 | 62% | ⏳ Pending |
| 2026-05-20 | Ibogaine brain plasticity finding sparks three NIH grants | 38% | ⏳ Pending |
| 2026-05-19 | Ibogaine stays illegal through 2029 because of heart risks, despite veteran pressure | 71% | ⏳ Pending |
| 2026-05-19 | Compass Pathways stock won't bounce back above $12.50 by August 2026 | 67% | ⏳ Pending |
| 2026-05-19 | Psilocybin-cocaine study gets mangled in 72 hours, then correction itself becomes a credibility scandal | 62% | ✗ Did not happen |
| 2026-05-18 | FDA will require heart screening before approving ibogaine studies | 82% | ⏳ Pending |
| 2026-05-18 | Researchers will study why psilocybin blocks cocaine relapse so effectively | 79% | ⏳ Pending |
| 2026-05-18 | Senate will hold ibogaine hearings with Stanford researchers by September 2026 | 78% | ⏳ Pending |
| 2026-05-18 | Major news outlet will expose ibogaine cardiac deaths in veteran programs | 76% | ⏳ Pending |
| 2026-05-18 | Compass stock outperforms MindMed on psilocybin depression data | 74% | ⏳ Pending |
| 2026-05-18 | Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT | 71% | ⏳ Pending |
| 2026-05-18 | California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psy | 70% | ⏳ Pending |
| 2026-05-17 | No psychedelic drug becomes legal medicine in US before 2028 | 82% | ⏳ Pending |
| 2026-05-17 | Psychedelic company stocks stay flat or lose money through 2026 | 68% | ⏳ Pending |
| 2026-05-17 | NIH funds 5+ ibogaine brain studies within 2 years, including non-hallucinogenic versions | 55% | ⏳ Pending |
| 2026-05-17 | FDA requires heart screening for ibogaine before therapeutic programs start | 52% | ⏳ Pending |
| 2026-05-17 | Anti-drug politicians cite psilocybin-cocaine study in congressional testimony within 12 months | 28% | ⏳ Pending |
| 2026-05-17 | Federal ibogaine cardiac safety rules delay therapeutic access by 18+ months | 18% | ⏳ Pending |
| 2026-05-16 | FDA demands heart screening before ibogaine trials expand | 62% | ⏳ Pending |
| 2026-05-16 | Three non-psychedelic ibogaine drugs will start lab testing | 61% | ⏳ Pending |
| 2026-05-16 | Congress forms psychedelic study group before 2027, no laws until 2028 | 58% | ⏳ Pending |
| 2026-05-16 | Two companies will ask FDA for fast-track psilocybin approval | 38% | ⏳ Pending |
| 2026-05-15 | Ibogaine stays illegal Schedule I drug through 2028 | 72% | ⏳ Pending |
| 2026-05-15 | Psilocybin-cocaine study sparks 10+ papers on brain mechanisms within 2 years | 62% | ⏳ Pending |
| 2026-05-15 | FDA publishes cardiac monitoring rules for ibogaine trials by end of 2026 | 41% | ⏳ Pending |
| 2026-05-15 | US government funds $50M+ ibogaine research and plasticity studies by late 2027 | 38% | ⏳ Pending |
| 2026-05-15 | Federal ibogaine cardiac monitoring rules written into law by August 2026 | 7% | ⏳ Pending |
| 2026-05-14 | States lead U.S. psychedelic policy ahead of federal action through 2027 | 72% | ⏳ Pending |
| 2026-05-14 | Ibogaine plasticity research spawns 5+ studies and 2 consortia by 2027 | 62% | ⏳ Pending |
| 2026-05-14 | Federal regulators or Congress formally address ibogaine cardiac safety by 2026 | 52% | ⏳ Pending |
| 2026-05-14 | FDA issues formal cardiac safety warning on ibogaine by late 2026 | 44% | ⏳ Pending |
| 2026-05-13 | Ibogaine won't get federal approval or rescheduling by early 2028 | 88% | ⏳ Pending |
| 2026-05-13 | No federal psychedelic law reform will reach a floor vote by end of 2028 | 78% | ⏳ Pending |
| 2026-05-13 | DEA will formally reject any ibogaine rescheduling request by 2028 | 68% | ⏳ Pending |
| 2026-05-13 | FDA will issue a cardiac safety warning on ibogaine by end of 2026 | 42% | ⏳ Pending |
| 2026-05-13 | A safer ibogaine alternative will raise over $30M by spring 2027 | 38% | ⏳ Pending |
| 2026-05-12 | Media will hype psilocybin cocaine study as 'cure,' then print corrections | 72% | ✗ Did not happen |
| 2026-05-12 | Congress holds public hearing on FDA's ibogaine policy and access | 55% | ⏳ Pending |
| 2026-05-12 | Research team launches new psilocybin addiction study with clear science | 52% | ⏳ Pending |
| 2026-05-12 | FDA warns the public about ibogaine heart rhythm dangers | 38% | ⏳ Pending |
| 2026-05-12 | FDA cardiac warning on ibogaine causes split in synthetic drug approval | 28% | ⏳ Pending |
| 2026-05-11 | Psilocybin research will spawn three competing theories about extinction without relapse | 72% | ⏳ Pending |
| 2026-05-11 | US states will pass four new psychedelic therapy laws while Congress stays frozen | 70% | ⏳ Pending |
| 2026-05-11 | Veterans will access psychedelic retreats outside the US by 5,000 by late 2026 | 55% | ⏳ Pending |
| 2026-05-11 | FDA will formally warn about ibogaine heart rhythm dangers by February 2027 | 52% | ⏳ Pending |
| 2026-05-11 | FDA or DEA will restrict ibogaine access before it expands in the US | 28% | ⏳ Pending |
| 2026-05-10 | States will open legal psilocybin therapy programs before federal law changes | 78% | ⏳ Pending |
| 2026-05-10 | FDA will demand repeat studies of psilocybin for cocaine addiction, approval by 2029 | 76% | ⏳ Pending |
| 2026-05-10 | Any approved ibogaine treatment will require mandatory heart monitoring, approval by 2028 | 74% | ⏳ Pending |
| 2026-05-10 | FDA issues cardiac safety warning on ibogaine, delaying approval 12–18 months | 72% | ⏳ Pending |
| 2026-05-10 | California passes legal psilocybin therapy law before end of 2026 | 52% | ⏳ Pending |
| 2026-05-10 | Congressional hearing triggered by veteran death in unregulated ibogaine treatment | 48% | ⏳ Pending |
| 2026-05-09 | Ibogaine development stalls due to cardiac safety concerns and regulatory blocks | 71% | ⏳ Pending |
| 2026-05-09 | FDA issues formal safety alert on ibogaine heart monitoring by end of 2026 | 62% | ⏳ Pending |
| 2026-05-09 | Two major companies file new psilocybin trials for cocaine addiction by 2026 | 52% | ⏳ Pending |
| 2026-05-09 | DEA blocks ibogaine rescheduling using new cardiac safety evidence by 2026 | 41% | ⏳ Pending |
| 2026-05-09 | Two psilocybin cocaine addiction trials launch within three months | 18% | ⏳ Pending |
| 2026-05-08 | No classical psychedelic will be rescheduled federally before 2028 | 80% | ⏳ Pending |
| 2026-05-08 | DEA delays psilocybin access by 18+ months after any FDA approval | 78% | ⏳ Pending |
| 2026-05-08 | FDA mandates heart monitoring for ibogaine, delaying veteran therapy access | 75% | ⏳ Pending |
| 2026-05-08 | A serious retreat injury will trigger state-level safety crackdowns by 2026 | 62% | ⏳ Pending |
| 2026-05-08 | Ibogaine splits into two paths: natural (restricted) and synthetic (faster approval) | 55% | ⏳ Pending |
| 2026-05-07 | Psilocybin rescheduling won't get a Congressional vote by January 2027 | 87% | ⏳ Pending |
| 2026-05-07 | No psychedelic rescheduling at federal level before 2028 | 85% | ⏳ Pending |
| 2026-05-07 | Ibogaine heart safety will block FDA progress through mid-2027 | 78% | ⏳ Pending |
| 2026-05-07 | FDA will warn about ibogaine heart rhythm dangers by end of 2026 | 72% | ⏳ Pending |
| 2026-05-07 | FDA won't publish SSRI-psychedelic interaction guidance by November 2027 | 70% | ⏳ Pending |
| 2026-05-06 | Medical schools will teach psychedelic therapy as standard psychiatry by 2028 | 94% | ⏳ Pending |
| 2026-05-06 | Microdosing becomes the fastest-growing psychedelic research area in 2026 | 91% | ⏳ Pending |
| 2026-05-06 | Both parties in Congress will formally acknowledge psychedelic therapy as legitimate medicine by end of 2026 | 88% | ⏳ Pending |
| 2026-05-06 | First psychedelic drug approved by FDA by end of 2027 | 87% | ⏳ Pending |
| 2026-05-06 | Psychedelic stocks will be higher in October than they were before Trump's order | 83% | ⏳ Pending |
| 2026-05-06 | Legal psychedelic therapy access program opens in the US before 2027 | 79% | ⏳ Pending |
| 2026-05-06 | Psilocybin shown to work for something beyond depression or PTSD | 76% | ⏳ Pending |
| 2026-05-06 | DEA begins formal process to move psilocybin out of Schedule I | 71% | ⏳ Pending |
| 2026-05-06 | A major drug company will buy or partner with a psychedelic biotech this year | 62% | ⏳ Pending |
| 2026-05-05 | Congress won't pass a standalone psychedelic bill before mid-2026 | 90% | ⏳ Pending |
| 2026-05-05 | Two more states will propose veteran psychedelic therapy access laws in 2026 | 78% | ⏳ Pending |
| 2026-05-05 | DEA will formally oppose any law letting veterans skip ibogaine review | 72% | ⏳ Pending |
| 2026-05-05 | FDA will require heart screening before testing ibogaine in humans | 62% | ⏳ Pending |
| 2026-05-05 | Ibogaine companies will publicly switch to safer chemical alternatives | 58% | ⏳ Pending |
| 2026-05-04 | FDA publishes heart-safety rules for ibogaine trials | 52% | ⏳ Pending |
| 2026-05-04 | Congressional hearing or federal probe triggered by ketamine clinic harm | 38% | ⏳ Pending |
| 2026-05-04 | FDA heart-safety guidance delays at least one ibogaine IND approval | 31% | ⏳ Pending |
| 2026-05-04 | Trial protocols cite SSRI drug interaction research in washout rules | 28% | ⏳ Pending |
| 2026-05-04 | SSRI washout rules mandated across multiple trials by mid-2026 | 14% | ⏳ Pending |
| 2026-05-03 | Any federal ibogaine law will require cardiac screening if it passes | 71% | ⏳ Pending |
| 2026-05-03 | Mind Medicine stock stays flat or down through September 2026 | 68% | ⏳ Pending |
| 2026-05-03 | Psychedelic biotech sector flat or down by early June 2026 | 61% | ⏳ Pending |
| 2026-05-03 | FDA issues formal cardiac screening rules for ibogaine trials | 52% | ⏳ Pending |
| 2026-05-03 | Ibogaine research shifts focus to brain chemistry pathway by 2028 | 48% | ⏳ Pending |
| 2026-05-03 | Cardiac screening becomes mandatory in one federal ibogaine bill or guidance | 44% | ⏳ Pending |
| 2026-05-02 | No psychedelic drug will be approved or rescheduled by end of 2026 | 82% | ⏳ Pending |
| 2026-05-02 | Psychedelic biotech stocks won't recover to 2024 peaks by September 2026 | 80% | ⏳ Pending |
| 2026-05-02 | FDA will mandate cardiac monitoring for ibogaine drug trials by January 2027 | 79% | ⏳ Pending |
| 2026-05-02 | Psychedelic biotech stocks will stay depressed through September 2026 | 78% | ⏳ Pending |
| 2026-05-02 | Ibogaine heart risk will force FDA to delay trials into 2027 | 72% | ⏳ Pending |
| 2026-05-01 | FDA requires heart screening tests for ibogaine drug trials | 62% | ⏳ Pending |
| 2026-05-01 | Two major psilocybin trials will require patients to stop antidepressants | 52% | ⏳ Pending |
| 2026-05-01 | Safer ibogaine versions will be worth much more than original | 48% | ⏳ Pending |
| 2026-05-01 | FDA may halt a psilocybin trial over treatment endpoint mismatch | 38% | ⏳ Pending |
| 2026-05-01 | Psilocybin trials will require antidepressant washout by July 2026 | 28% | ⏳ Pending |
| 2026-04-30 | DEA keeps psilocybin and MDMA illegal through October 2026 | 88% | ⏳ Pending |
| 2026-04-30 | MAPS or Compass publishes psilocybin trial safety or enrollment update | 80% | ⏳ Pending |
| 2026-04-30 | Congress introduces a bipartisan bill supporting psychedelic research | 62% | ⏳ Pending |
| 2026-04-30 | Compass or MAPS announces Phase 3 results or FDA pre-approval meeting | 55% | ⏳ Pending |
| 2026-04-30 | Congress introduces bill protecting Indigenous plant medicine and sovereignty rights | 42% | ⏳ Pending |
| 2026-04-30 | One US state passes a psychedelic therapy or decriminalization law | 38% | ⏳ Pending |
| 2026-04-30 | US insurer or Medicare announces psychedelic therapy reimbursement guidance | 8% | ⏳ Pending |
| 2026-04-29 | No ibogaine product gets FDA approval before 2030 | 84% | ⏳ Pending |
| 2026-04-29 | DEA keeps all psychedelics in Schedule I without rescheduling by 2028 | 77% | ⏳ Pending |
| 2026-04-29 | No federal ibogaine approval pathway established by 2029 | 76% | ⏳ Pending |
| 2026-04-29 | Three more states pass ibogaine access laws for veterans by end of 2027 | 62% | ⏳ Pending |
| 2026-04-29 | Five independent studies replicate fluoxetine-psychedelic interaction by April 2028 | 58% | ⏳ Pending |
| 2026-04-29 | Fluoxetine-psychedelic screening becomes required in federal psychedelic trials by April 2028 | 52% | ⏳ Pending |
| 2026-04-29 | FDA issues protocol guidance on fluoxetine-psychedelic data by Q2 2027 | 45% | ⏳ Pending |
| 2026-04-28 | No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 202 | 77% | ⏳ Pending |
| 2026-04-28 | Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibog | 70% | ⏳ Pending |
| 2026-04-28 | Oxa-noribogaine enters a human Phase 1 clinical trial before October 31, 2027 | 62% | ⏳ Pending |
| 2026-04-28 | CMPS (Compass Pathways) closes below $7.00 on at least one trading day before June 30, 2026 | 45% | ✗ Did not happen |
| 2026-04-28 | FDA issues a formal guidance document specifically addressing psychedelic-SSRI pharmacodynamic interactions and washout | 38% | ⏳ Pending |
| 2026-04-27 | Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weapo | 78% | ⏳ Pending |
| 2026-04-27 | Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac | 76% | ○ Void (unmeasurable) |
| 2026-04-27 | Psilocybin will be the first classic psychedelic to receive FDA NDA acceptance for review for treatment-resistant MDD, w | 74% | ⏳ Pending |
| 2026-04-27 | Fluoxetine-psychedelic interaction data will be incorporated into FDA guidance requiring standardized SSRI washout crite | 72% | ⏳ Pending |